NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities
June 2, 2025 12:02 PM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $201.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Ascendis (ASND) announced the NDA submission for TransCon CNP in achondroplasia (ACH) was accepted by the FDA with priority review with an assigned... More
